Dr Reddy’s Is Pushing For Progress On Multiple Fronts

CEO Sets Out How The Firm Is Remaining Competitive In Generics And Biosimilars

30 Jan 2023

Whether in the competitive world of US generics, the growing global biosimilars arena, or promising new geographical markets, Dr Reddy’s is seeking to capitalize on its strengths to remain competitive while also pushing forward with ESG goals, CEO Erez Israeli tells Generics Bulletin.

Multiple arrows forward — Dr Reddy’s is pushing ahead in multiple business segments • Source: Shutterstock

With Dr Reddy’s global operations comprising a wide range of different activities – each of which falls under one of two “Horizons”, with the first comprising core interests in active pharmaceutical ingredients, generics and biosimilars while the second covers more innovative businesses (see sidebar) – the company is confronting its competitors on a number of different fronts.

However, CEO Erez Israeli tells Generics Bulletin in the second part of an exclusive interview, in each market the Indian...